Lipigon signs new deal in billion dollar market
Umeå-based Lipigon Pharmaceuticals has signed a new deal and taken over the patent portfolio for a number of drug candidates that could help treat cardiovascular diseases. “The market in treatments for various blood fat disorders amounts to several billion dollars. This is a very important opportunity for us,” says Stefan K Nilsson, CEO of Lipigon.